Program
tarperprumig
Also written as “Tarperprumig”, “ALXN1820” and “ALXN1820 SC”.
Its studies are mostly in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis · Anemia, Sickle Cell, led by AstraZeneca.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 31 open or running | phase 2since Sep 15, 2022 | Nov 13, 2020 | Oct 11, 2027phase 2 · NCT07160608 |
- Named in AstraZeneca’s own pipeline as
tarperprumig
, phase 2, as of Oct 30, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 13, 2020First study: phase 1 study in HealthyFirst studyNCT04631562 · 66 enrolled · Australia, United Kingdom
- Sep 15, 2022Phase 2 study in Anemia, Sickle CellNCT05565092 · 2 enrolled · United States
- Jul 21, 2025Phase 2 study in Anti-Neutrophil Cytoplasmic Antibody-Associated VasculitisNCT07160608 · 78 enrolled · Argentina, Australia, Brazil and more
Ahead
- Oct 11, 2027Primary completion: phase 2 study in Anti-Neutrophil Cytoplasmic Antibody-Associated VasculitisNCT07160608
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07160608Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis · Argentina, Australia, Brazil and more | 2 | Active, not recruiting | Oct 11, 2027 | 78 |
| NCT05565092Anemia, Sickle Cell · United States | 2 | Terminated | Jan 9, 2024 | 2 |
| NCT04631562Healthy · Australia, United Kingdom | 1 | Completed | Sep 1, 2022 | 66 |
How it is read
Names in the registry
- “Tarperprumig”, 1 entry
- “ALXN1820”, 1 entry
- “ALXN1820 SC”, 1 entry
- “ALXN1820 IV”, 1 entry
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.